Drugs / HC 5404
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04834778 | Jun 2021 → Dec 2023 | breast cancer, gastric cancer, renal cell carcinoma, small cell lung carcinoma | HiberCell, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HC 5404 | “HC 5404-FU (hemi fumarate salt of HC 5404) is a novel, highly selective, and potent PERK inhibitor.” NCT04834778 ↗ |
| Action | Inhibit | “HC 5404-FU (hemi fumarate salt of HC 5404) is a novel, highly selective, and potent PERK inhibitor.” NCT04834778 ↗ |
| Route | Oral | “HC 5404-FU will be orally administered BID every day with food or within 30 minutes of completing a meal” NCT04834778 ↗ |